Effects of Inhalable Microparticles of Seonpyejeongcheon-Tang in an Asthma Mouse Model: - Effects of Microparticles of SJT

Overview

Journal J Pharmacopuncture

Date 2017 Jan 19

PMID 28097040

Citations 3

Authors

Won-Kyung Yang

Chul-Hwa Lee

Min-Hee Kim

Seung-Hyeong Kim

Hae-Yoon Choi

Yoon Yeo

Yang-Chun Park

Affiliations

Soon will be listed here.

Abstract

Objectives: Allergic asthma generally presents with symptoms of wheezing, coughing, breathlessness, and airway inflammation. Seonpyejeongcheon-tang (SJT) consists of 12 herbs. It originated from Jeongcheon-tang (JT), also known as Ding-chuan-tang, composed of 7 herbs, in She-sheng-zhong-miao-fang. This study aimed to evaluate the effects of local delivery of SJT inhalable microparticles in an asthma mouse model.

Methods: Microparticles containing SJT were produced by spray-drying with leucine as an excipient. SJT microparticles were evaluated with respect to their aerodynamic properties, cytotoxicity, toxicity, and therapeutic effects on ovalbumin (OVA)-induced asthma in comparison with orally-administered SJT.

Results: SJT microparticles provided desirable aerodynamic properties (fine particle fraction of 48.9% ± 6.4% and mass median aerodynamic diameter of 3.7 ± 0.3 μm). SJT microparticles did not show any cytotoxicity against RAW 264.7 macrophages at concentrations of 0.01 - 3 mg/mL. Inhaled SJT microparticles decreased the levels of IL-4, IL-5, IL-13, IL-17A, eotaxin and OVA-IgE in bronchoalveolar lavage fluid (BALF) in mice with OVA-induced asthma. These effects were verified by histological evaluation of the levels of infiltration of inflammatory cells and collagen, destructions of alveoli and bronchioles, and hyperplasia of goblet cells in lung tissues. The effects of SJT microparticles in the asthma model were equivalent to those of orally-administered SJT extract.

Conclusion: This study suggests that SJT is a promising agent for inhalation therapy for patients with asthma.

Citing Articles

Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases.

Pulivendala G, Bale S, Godugu C Drug Deliv Transl Res. 2019; 10(2):339-353.

PMID: 31872342 DOI: 10.1007/s13346-019-00690-7.

Utilization of Chinese medicine for respiratory discomforts by patients with a medical history of tuberculosis in Taiwan.

Yang S, Lin Y, Wu M, Chiang J, Yang P, Hsia T BMC Complement Altern Med. 2018; 18(1):313.

PMID: 30497462 PMC: 6267063. DOI: 10.1186/s12906-018-2377-4.

Identification of Epigenetic Mechanisms Involved in the Anti-Asthmatic Effects of Seed Extract Based on a Multi-Omics Approach.

Baek S, Chun J, Kang T, Seo Y, Kim S, Seong B Molecules. 2018; 23(11).

PMID: 30400597 PMC: 6278437. DOI: 10.3390/molecules23112879.

References

Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky M, Yeo Y . Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009; 30(10):1947-53. DOI: 10.1016/j.biomaterials.2008.12.044. View

Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W . Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006; 28(5):1042-50. DOI: 10.1183/09031936.00074905. View

Barnes P . Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008; 8(3):183-92. DOI: 10.1038/nri2254. View

Sanderson C . Interleukin-5, eosinophils, and disease. Blood. 1992; 79(12):3101-9. View

Ibrahim B, Jun S, Lee M, Kang S, Yeo Y . Development of inhalable dry powder formulation of basic fibroblast growth factor. Int J Pharm. 2009; 385(1-2):66-72. DOI: 10.1016/j.ijpharm.2009.10.029. View

Tillie-Leblond I, Gosset P, Tonnel A . Inflammatory events in severe acute asthma. Allergy. 2004; 60(1):23-9. DOI: 10.1111/j.1398-9995.2005.00632.x. View

Walker C, Kaegi M, Braun P, Blaser K . Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol. 1991; 88(6):935-42. DOI: 10.1016/0091-6749(91)90251-i. View

Park Y, Jin M, Kim S, Kim M, Namgung U, Yeo Y . Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. J Ethnopharmacol. 2013; 151(1):123-30. DOI: 10.1016/j.jep.2013.10.013. View

McKinnon M, Page K, Uings I, Banks M, Fattah D, Proudfoot A . An interleukin 5 mutant distinguishes between two functional responses in human eosinophils. J Exp Med. 1997; 186(1):121-9. PMC: 2198963. DOI: 10.1084/jem.186.1.121. View

10.

Tomkinson A, Duez C, Cieslewicz G, Pratt J, Joetham A, Shanafelt M . A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol. 2001; 166(9):5792-800. DOI: 10.4049/jimmunol.166.9.5792. View

11.

Kay A . Asthma and inflammation. J Allergy Clin Immunol. 1991; 87(5):893-910. DOI: 10.1016/0091-6749(91)90408-g. View

12.

Epstein M . Targeting memory Th2 cells for the treatment of allergic asthma. Pharmacol Ther. 2005; 109(1-2):107-36. DOI: 10.1016/j.pharmthera.2005.06.006. View

13.

Ben-Jebria A, Chen D, Eskew M, Vanbever R, Langer R, Edwards D . Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res. 1999; 16(4):555-61. DOI: 10.1023/a:1018879331061. View

14.

Caramori G, Pandit A, Papi A . Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease?. Curr Opin Allergy Clin Immunol. 2005; 5(1):77-83. DOI: 10.1097/00130832-200502000-00014. View

15.

Bousquet J, Jeffery P, Busse W, Johnson M, Vignola A . Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161(5):1720-45. DOI: 10.1164/ajrccm.161.5.9903102. View

16.

Duret C, Wauthoz N, Merlos R, Goole J, Maris C, Roland I . In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice. Eur J Pharm Biopharm. 2012; 81(3):627-34. DOI: 10.1016/j.ejpb.2012.04.004. View

17.

Bousquet J, Chanez P, Lacoste J, Barneon G, Ghavanian N, ENANDER I . Eosinophilic inflammation in asthma. N Engl J Med. 1990; 323(15):1033-9. DOI: 10.1056/NEJM199010113231505. View

18.

Kao S, Chang C, Chen Y, Chiang S, Lin J . Effects of Ding-Chuan-Tang on bronchoconstriction and airway leucocyte infiltration in sensitized guinea pigs. Immunopharmacol Immunotoxicol. 2004; 26(1):113-24. DOI: 10.1081/iph-120029949. View

19.

Barrett N, Austen K . Innate cells and T helper 2 cell immunity in airway inflammation. Immunity. 2009; 31(3):425-37. PMC: 3353417. DOI: 10.1016/j.immuni.2009.08.014. View

20.

Yang Y, Tsifansky M, Wu C, Yang H, Schmidt G, Yeo Y . Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res. 2009; 27(1):151-60. DOI: 10.1007/s11095-009-9991-2. View